Smoking Cessation After Initial Treatment Failure With Varenicline or Nicotine Replacement

伐尼克兰 医学 禁欲 尼古丁替代疗法 戒烟 尼古丁贴片 随机对照试验 安慰剂 剂量 麻醉 内科学 精神科 病理 替代医学
作者
Paul M. Cinciripini,Charles E. Green,Sanjay Shete,Jennifer A. Minnix,Jason D. Robinson,Yong Cui,Seokhun Kim,George Kypriotakis,Diane Beneventi,Janice A. Blalock,Francesco Versace,Maher Karam‐Hage
出处
期刊:JAMA [American Medical Association]
卷期号:331 (20): 1722-1722 被引量:2
标识
DOI:10.1001/jama.2024.4183
摘要

Importance Most people who smoke do not quit on their initial attempt. Objective To determine the best subsequent strategy for nonabstinence following initial treatment with varenicline or combined nicotine replacement therapy (CNRT). Design, Setting, and Participants Using a double-blind, placebo-controlled, sequential multiple assignment randomized trial, 490 volunteers were randomized to receive 6 weeks of varenicline or CNRT. After 6 weeks, nonabstainers were rerandomized to continue, switch, or increase medication dosage for 6 additional weeks. The study was conducted from June 2015 through October 2019 in a Texas tobacco treatment clinic. Interventions The initial treatment was 2 mg/d of varenicline or the combined replacement therapy of a 21-mg patch plus 2-mg lozenge. The rerandomized participants either continued with their initial therapies, switched between varenicline and CNRT, or increased dosages either to 3-mg or more of varenicline or to a 42-mg patch and lozenges. All received weekly brief counseling. Main Outcomes and Measures Biochemically verified 7-day point prevalence abstinence at the end of treatment at 12 weeks. Results The 490 randomized participants (210 female [43%], 287 non-Hispanic White [58%], mean age, 48.1 years) smoked an average of 20 cigarettes per day. After the first phase, 54 participants in the CNRT group were abstinent and continued their therapy; of the 191 who were not abstinent, 151 were rerandomized, and the 40 who did not return for rerandomization were assigned to continue their initial CNRT condition in phase 2. The end-of-treatment abstinence rate for the 191 phase 1 nonabstainers was 8% (95% credible interval [CrI], 6% to 10%) for the 90 (47%) who continued at the dosage condition, 14% (CrI, 10% to 18%) for the 50 (33%) who increased their dosage, and 14% (95% CrI, 10% to 18%) for the 51 (34%) who switched to varenicline (absolute risk difference [RD], 6%; 95% CrI, 6% to 11%) with more than 99% posterior probability that either strategy conferred benefit over continuing the initial dosage. After the first phase, 88 participants in the varenicline group were abstinent and continued their therapy; of the 157 who were not abstinent, 122 were rerandomized and 35 who did not return for rerandomization were assigned to continue with the varenicline condition. The end-of-treatment abstinence rate for the 157 phase 1 nonabstainers was 20% (95% CrI, 16% to 26%) for the 39 (32%) who increased their varenicline dosage, 0 (95% CrI, 0 to 0) for the 41 (34%) who switched CNRT, and 3% (95% CrI, 1% to 4%) for the 77 (49%) who were assigned to the continued varenicline condition (absolute RD, −3%; 95% CrI, −4% to −1%) with more than 99% posterior probability that continuing varenicline at the initial dosage was worse than switching to a higher dosage. Furthermore, increasing the varenicline dosage had an absolute RD of 18% (95% CrI, 13% to 24%) and a more than 99% posterior probability of conferring benefit. The secondary outcome of continuous abstinence at 6 months indicated that only increased dosages of the CNRT and varenicline provided benefit over continuation of the initial treatment dosages. Conclusions and Relevance For individuals who smoked but did not achieve abstinence after treatment with varenicline, increasing the dosage enhanced abstinence vs continuing, whereas for nonabstainers initially treated with CNRT, a dosage increase or switch to varenicline enhanced abstinence and may be viable rescue strategies. Trial Registration ClinicalTrials.gov Identifier: NCT02271919
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
HELAOBAN发布了新的文献求助10
2秒前
3秒前
科目三应助tzy采纳,获得10
3秒前
easton发布了新的文献求助10
3秒前
xiaji发布了新的文献求助10
3秒前
3秒前
3秒前
4秒前
Owen应助旺旺采纳,获得10
6秒前
NexusExplorer应助迷人的舞仙采纳,获得10
6秒前
忍冬完成签到,获得积分10
6秒前
Liwia发布了新的文献求助10
7秒前
泡泡糖发布了新的文献求助10
7秒前
小二郎应助luonayi采纳,获得10
7秒前
7秒前
8秒前
8秒前
英俊的铭应助cccc采纳,获得10
8秒前
8秒前
9秒前
梁晓雯发布了新的文献求助10
9秒前
maodoudou完成签到,获得积分20
10秒前
415关注了科研通微信公众号
10秒前
10秒前
恬昱发布了新的文献求助10
10秒前
10秒前
Ljc发布了新的文献求助10
10秒前
10秒前
11秒前
双月发布了新的文献求助10
12秒前
12秒前
12秒前
养乐多发布了新的文献求助10
13秒前
科目三应助白冰采纳,获得10
13秒前
13秒前
鲤鱼安青发布了新的文献求助10
13秒前
13秒前
深情安青应助Ayanami采纳,获得10
14秒前
紫色风铃完成签到,获得积分10
14秒前
豆子应助谦让的振家采纳,获得20
14秒前
高分求助中
Picture Books with Same-sex Parented Families: Unintentional Censorship 700
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
Nucleophilic substitution in azasydnone-modified dinitroanisoles 500
不知道标题是什么 500
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
Effective Learning and Mental Wellbeing 300
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3974844
求助须知:如何正确求助?哪些是违规求助? 3519270
关于积分的说明 11197844
捐赠科研通 3255496
什么是DOI,文献DOI怎么找? 1797791
邀请新用户注册赠送积分活动 877187
科研通“疑难数据库(出版商)”最低求助积分说明 806202